ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)

Launched by INDIANA UNIVERSITY · Mar 21, 2025

Keywords

ClinConnect Summary

The INTERPRET trial is a study designed to help researchers understand how the immune system responds to cancer treatments known as immunotherapy. This type of therapy helps the body fight cancer by boosting its own immune responses. In this study, blood samples will be collected from participants at various times before and during their treatment to see how these samples relate to their responses to the therapy and any side effects they may experience.

To be eligible for this study, participants need to be at least 18 years old, have a confirmed diagnosis of cancer, and be starting a treatment plan that includes immunotherapy. The trial is not yet recruiting participants, but once it begins, those who join will provide blood samples at specific times as their treatment progresses. This research could lead to better ways to predict how well immunotherapy will work for patients and help manage any potential side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥ 18 years old at the time of informed consent.
• • 2. Have a diagnosis of cancer and initiating therapy with single agent or combination therapy that includes an immunotherapy (see Appendix 16.1 for list of immunotherapy classes).
• • 3. Ability to provide written informed consent and HIPAA authorization.
• Exclusion Criteria:
• • 1. Not meeting any of the previously described inclusion criteria.